HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ying Gu Selected Research

hematoporphyrin monomethyl ether

9/2018A dose-finding study for hemoporfin in photodynamic therapy for port-wine stain: A multicenter randomized double-blind phase IIb trial.
1/2016Hemoporfin Photodynamic Therapy for Port-Wine Stain: A Randomized Controlled Trial.
1/2014Retinal injury thresholds for 532, 578, and 630 nm lasers in connection to photodynamic therapy for choroidal neovascularization.
4/2011Effect of hematoporphyrin monomethyl ether-mediated photodynamic therapy on hypertrophic scar fibroblasts.
2/2011Efficacy and safety of hemoporfin in photodynamic therapy for port-wine stain: a multicenter and open-labeled phase IIa study.
7/2010Effects of photodynamic therapy using hematoporphyrin monomethyl ether on experimental choroidal neovascularization.
9/2007[Effect of HMME-PDT on hyperplastic scar in rabbit ear model].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ying Gu Research Topics

Disease

53Neoplasms (Cancer)
11/2022 - 04/2003
25Port-Wine Stain (Nevus Flammeus)
02/2021 - 06/2007
19Infections
01/2022 - 12/2003
12Periodontitis
01/2022 - 03/2010
9Inflammation (Inflammations)
04/2022 - 12/2011
9Leukemia
01/2022 - 08/2006
7Neoplasm Metastasis (Metastasis)
09/2019 - 01/2005
6Colorectal Neoplasms (Colorectal Cancer)
06/2022 - 12/2004
6Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2021 - 03/2014
6Hepatitis E
01/2020 - 01/2004
6Virus Diseases (Viral Diseases)
01/2019 - 01/2017
5Wounds and Injuries (Trauma)
04/2022 - 09/2007
5Periodontal Diseases (Periodontal Disease)
01/2022 - 12/2011
5Cardiovascular Diseases (Cardiovascular Disease)
04/2021 - 12/2011
5Skin Diseases (Skin Disease)
06/2016 - 03/2010
4Aneuploidy (Aneuploid)
02/2021 - 10/2015
4Carcinoma (Carcinomatosis)
11/2017 - 04/2003
4Stomach Neoplasms (Stomach Cancer)
03/2010 - 09/2005
3Alveolar Bone Loss
01/2022 - 01/2019
3Breast Neoplasms (Breast Cancer)
01/2022 - 01/2005
3Obesity
12/2021 - 10/2010
3Hyperglycemia
01/2021 - 01/2016
3Hemorrhage
02/2020 - 06/2012
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2020 - 05/2007
3Hyperpigmentation
09/2018 - 09/2011
3Papillomavirus Infections
01/2017 - 06/2015
3Vascular Diseases (Vascular Disease)
01/2017 - 03/2009
3Choroidal Neovascularization
05/2015 - 07/2010
3Macular Degeneration (Age-Related Maculopathy)
05/2015 - 04/2010
3Heart Diseases (Heart Disease)
01/2014 - 03/2013
3BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
12/2012 - 08/2006
2Fatty Liver
01/2022 - 01/2016
2Insulin Resistance
01/2022 - 01/2016
2Heart Failure
01/2022 - 01/2014
2Pain (Aches)
01/2022 - 06/2014
2COVID-19
01/2022 - 12/2020
2Congenital Heart Defects (Congenital Heart Defect)
12/2021 - 01/2020
2Chronic Periodontitis
09/2021 - 01/2020
2Acute Coronary Syndrome
04/2021 - 09/2012
2Thalassemia
01/2021 - 01/2020
2Osteoporosis
01/2021 - 12/2018
2Carcinogenesis
01/2021 - 04/2003

Drug/Important Bio-Agent (IBA)

361-phenyl-3,3-dimethyltriazene (PDT)IBA
06/2022 - 12/2004
19VaccinesIBA
01/2022 - 01/2005
13Proteins (Proteins, Gene)FDA Link
01/2022 - 08/2006
11Matrix Metalloproteinases (MMPs)IBA
01/2022 - 01/2005
10Photosensitizing Agents (Photosensitizers)IBA
06/2022 - 02/2010
10Pharmaceutical PreparationsIBA
10/2021 - 05/2007
8CytokinesIBA
01/2022 - 12/2011
7Anti-Bacterial Agents (Antibiotics)IBA
01/2019 - 03/2010
7hematoporphyrin monomethyl etherIBA
09/2018 - 09/2007
6CurcuminIBA
01/2022 - 01/2013
6Biomarkers (Surrogate Marker)IBA
12/2021 - 12/2003
6DNA (Deoxyribonucleic Acid)IBA
07/2020 - 01/2015
5Peptides (Polypeptides)IBA
06/2022 - 04/2005
5AntibodiesIBA
04/2021 - 12/2003
5RNA (Ribonucleic Acid)IBA
01/2021 - 04/2010
5Biological ProductsIBA
01/2020 - 01/2010
5CateninsIBA
09/2019 - 11/2012
5Fluorouracil (Carac)FDA LinkGeneric
11/2017 - 05/2007
4EpitopesIBA
06/2022 - 06/2008
4Indicators and Reagents (Reagents)IBA
01/2022 - 06/2011
4Neutralizing AntibodiesIBA
01/2022 - 01/2017
4Monoclonal AntibodiesIBA
07/2020 - 10/2015
4Weichang'anIBA
09/2019 - 09/2005
4TetracyclinesIBA
06/2016 - 01/2005
4Doxycycline (Periostat)FDA LinkGeneric
06/2016 - 03/2010
4Therapeutic UsesIBA
10/2015 - 02/2010
3Interleukin-6 (Interleukin 6)IBA
01/2022 - 12/2011
3Oxygen (Dioxygen)IBA
01/2022 - 12/2010
3Oncogene Proteins (Oncogene Protein)IBA
10/2021 - 06/2015
3EndotoxinsIBA
09/2021 - 12/2011
3Messenger RNA (mRNA)IBA
01/2021 - 11/2012
3Long Noncoding RNAIBA
01/2021 - 01/2013
31,7- bis(4- hydroxyphenyl)- 4- N- phenylaminocarbonylhepta- 1,6- dien- 3,5- dioneIBA
01/2021 - 01/2016
3Tetracycline (Achromycin)FDA LinkGeneric
06/2016 - 01/2005
3hypocrellin BIBA
05/2015 - 03/2012
3Reactive Oxygen Species (Oxygen Radicals)IBA
06/2014 - 12/2004
3berbamine (penduline)IBA
12/2012 - 08/2006
3tetracycline CMT-3IBA
01/2012 - 01/2005
3Singlet OxygenIBA
09/2011 - 12/2004
3Immunoglobulin G (IgG)IBA
06/2011 - 12/2003
2Epithelial Cell Adhesion MoleculeIBA
11/2022 - 09/2021
2AntigensIBA
06/2022 - 04/2021
2CollagenIBA
04/2022 - 09/2007
2LipidsIBA
01/2022 - 12/2021
2Matrix Metalloproteinase InhibitorsIBA
01/2022 - 01/2020
2Adenosine Triphosphate (ATP)IBA
01/2022 - 12/2012
2LipopolysaccharidesIBA
09/2021 - 01/2019
2C-Reactive ProteinIBA
04/2021 - 12/2011
2dichlorobis(azomycin)platinum IIIBA
02/2021 - 10/2015
2Antiviral Agents (Antivirals)IBA
01/2021 - 01/2018
2Streptozocin (Streptozotocin)FDA Link
01/2021 - 01/2016

Therapy/Procedure

34Photochemotherapy (Photodynamic Therapy)
06/2022 - 09/2007
30Therapeutics
11/2022 - 06/2007
14Lasers (Laser)
06/2016 - 06/2007
6Drug Therapy (Chemotherapy)
07/2020 - 12/2004
3Aftercare (After-Treatment)
09/2018 - 08/2006
2Immunotherapy
06/2022 - 01/2013
2Hematopoietic Stem Cell Transplantation
01/2021 - 01/2019